Abstract
Human immunodeficiency virus type 1 (HIV) infects macrophages and microglia in the CNS and frequently causes neurocognitive impairment. Although antiviral therapy generally reduces the viral load in the CNS and improves HIV-associated neurological dysfunction, most current antiviral drugs have poor CNS penetrance and cannot completely suppress viral replication. Furthermore, drug-resistance mutations can evolve independently in the CNS. Thus, a longlived viral reservoir persists in macrophages and microglia in the brain despite antiviral therapy. This review discusses mechanisms underlying the neurotropism of HIV, focusing on the role of the HIV envelope glycoproteins and their interactions with CD4 and the chemokine receptors CCR5 and CXCR4. We review data from studies of neurotropic HIV derived from the brains of patients with HIV-associated neurocognitive impairment as well as studies of nonhuman primate models. Understanding mechanisms that underlie HIV neurotropism and neurovirulence is critical for development of therapeutics to inhibit CNS infection and preventing neurological injury in HIV-infected individuals.
Keywords: HIV, CCR5, macrophages, microglia, neurotropism
Current HIV Research
Title: Mechanisms of HIV-1 Neurotropism
Volume: 4 Issue: 3
Author(s): Rebecca Dunfee, Elaine R. Thomas, Paul R. Gorry, Jianbin Wang, Petronela Ancuta and Dana Gabuzda
Affiliation:
Keywords: HIV, CCR5, macrophages, microglia, neurotropism
Abstract: Human immunodeficiency virus type 1 (HIV) infects macrophages and microglia in the CNS and frequently causes neurocognitive impairment. Although antiviral therapy generally reduces the viral load in the CNS and improves HIV-associated neurological dysfunction, most current antiviral drugs have poor CNS penetrance and cannot completely suppress viral replication. Furthermore, drug-resistance mutations can evolve independently in the CNS. Thus, a longlived viral reservoir persists in macrophages and microglia in the brain despite antiviral therapy. This review discusses mechanisms underlying the neurotropism of HIV, focusing on the role of the HIV envelope glycoproteins and their interactions with CD4 and the chemokine receptors CCR5 and CXCR4. We review data from studies of neurotropic HIV derived from the brains of patients with HIV-associated neurocognitive impairment as well as studies of nonhuman primate models. Understanding mechanisms that underlie HIV neurotropism and neurovirulence is critical for development of therapeutics to inhibit CNS infection and preventing neurological injury in HIV-infected individuals.
Export Options
About this article
Cite this article as:
Dunfee Rebecca, Thomas R. Elaine, Gorry R. Paul, Wang Jianbin, Ancuta Petronela and Gabuzda Dana, Mechanisms of HIV-1 Neurotropism, Current HIV Research 2006; 4 (3) . https://dx.doi.org/10.2174/157016206777709500
DOI https://dx.doi.org/10.2174/157016206777709500 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Chemogenomics and Parasitology: Small Molecules and Cell-Based Assays to Study Infectious Processes
Combinatorial Chemistry & High Throughput Screening The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses Cytokine Network in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Alternative Medicine as a Treatment Option for COVID-19
Current Traditional Medicine Biomedical Consequences of Alcohol Use Disorders in the HIV-Infected Host
Current HIV Research Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design